請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52297
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張鑫(Shin C. Chang) | |
dc.contributor.author | Hao-Yu Wang | en |
dc.contributor.author | 王浩宇 | zh_TW |
dc.date.accessioned | 2021-06-15T16:11:17Z | - |
dc.date.available | 2020-09-25 | |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-18 | |
dc.identifier.citation | Afdhal N, Zeuzem S, Kwo P, ION-1 Investigators, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine 2014; 370(20):1889–1898. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272(5270): 1955-1958. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. Journal of Virology 1993; 67(7): 3835-3844. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Advances in Virus Research 2004; 63: 71-180. Berkman N, John M, Roesems G, Jose PJ, Barnes PJ, Chung KF. Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. Journal of Immunology 1995; 155: 4412–4418. Canque B, Rosenzwajg M, Gey A, Tartour E, Fridman WH, Gluckman JC. Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood 1996; 87(5): 2011-2019. Chang SC, Yen JH, Kang HY, Jang MH, Chang MF. Nuclear localization signals in the core protein of hepatitis C virus. Biochemical and Biophysical Research Communications 1994; 205(2):1284-1290. Cheng D, Zhao L, Zhang L, Jiang Y, Tian Y, Xiao X, Gong G. p53 controls hepatitis C virus non-structural protein 5A-mediated downregulation of GADD45α expression via the NF-κB and PI3K-Akt pathways. Journal of General Virology 2013; 94(Pt 2): 326-335. Choi SJ, Oba T, Callander NS, Jelinek DF, Roodman GD. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood 2003; 101(10): 3778-3783. Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 80(244): 359-362. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+T cells. Science 1995; 270(5243): 1811-1815. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker C. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-449. Danforth JM, Strieter RM, Kunkel SL, Arenberg DA, VanOtteren GM, Standiford TJ. Macrophage inflammatory protein-1 alpha expression in vivo and in vitro: the role of lipoteichoic acid. Clinical Immunology and Immunopathology 1995; 74(1): 77-83. Elazar M, Cheong KH, Liu P, Greenberg HB, Rice CM, Glenn JS. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. Journal of Virology 2003; 77(10): 6055-6061. Elazar M, Liu P, Rice CM, Glenn JS. An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. Journal of Virology 2004; 78(20): 11393-113400. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. The Journal of Clinical Investigation 1995; 96(1): 224-230. Evans MJ, Rice CM, Goff SP. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proceedings of the National Academy of Sciences of the United States of America 2004; 101(35): 13038-13043. Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Molecular and Cellular Biology 1998; 18(9): 5208-5218. Gale M Jr, Kwieciszewski B, Dossett M, Nakao H, Katze MG. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. Journal of Virology 1999; 73(8): 6506-6516. Georgopoulou U, Caravokiri K, Mavromara P. Suppression of the ERK1/2 signaling pathway from HCV NS5A protein expressed by herpes simplex recombinant viruses. Archives of Virology 2003; 148(2): 237-251. Gong GZ, Jiang YF, He Y, Lai LY, Zhu YH, Su XS. HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding. World Journal of Gastroenterology 2004; 10(15): 2223-2227. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. Journal of Virology 1993; 67(8): 4665-4675. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antiviral Therapy 2005; 10(1): 1-11. Ide Y, Zhang L, Chen M, Inchauspe G, Bahl C, Sasaguri Y, Padmanabhan R. Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A. Gene 1996; 182(1-2): 203-211. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. New England Journal of Medicine 2011; 364(25): 2405-2416. Jirasko V, Montserret R, Lee JY, Gouttenoire J, Moradpour D, Penin F, Bartenschlager R. Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. PLoS Pathogens 2010; 6(12): e1001233. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. Journal of Virology 2007; 81(16): 8374-8383. Kaneko T, Tanji Y, Satoh S, Hijikata M, Asabe S, Kimura K, Shimotohno K. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochemical and Biophysical Research Communications 1994; 205(1): 320-326. Kim DW, Gwack Y, Han JH, Choe J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochemical and Biophysical Research Communications 1995; 215(1): 160-166. Krzysiek R, Lefèvre EA, Zou W, Foussat A, Bernard J, Portier A, Galanaud P, Richard Y. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. Journal of Immunology 1999; 162(8): 4455-4463. Kuo YC, Chen IY, Chang SC, Wu SC, Hung TM, Lee PH, Shimotohno K, Chang MF. Hepatitis C virus NS5A protein enhances gluconeogenesis through upregulation of Akt-/JNK-PEPCK signalling pathways. Liver International 2014; 34(9): 1358-1368. Larrubia JR, Calvino M, Benito S, Sanz-de-Villalobos E, Perna C, Pérez-Hornedo J, González-Mateos F, García-Garzón S, Bienvenido A, Parra T. The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. Journal of Hepatology 2007; 47(5): 632-641. Lauer GM, Walker BD. Hepatitis C virus infection. New England Journal of Medicine 2001; 345(1): 41-52. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine 2013; 368:1878-1887. Lichterfeld M, Leifeld L, Nischalke HD, Rockstroh JK, Hess L, Sauerbruch T, Spengler U. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. The Journal of Infectious Diseases 2002; 185(12): 1803–1807. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86(3): 367-377. Lukacs NW, Strieter RM, Elner VM, Evanoff HL , Burdick M, Kunkel SL. Intercellular adhesion molecule-1 mediates the expression of monocyte-derived MIP-1 alpha during monocyte-endothelial cell interactions. Blood 1994; 83(5): 1174-1178. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. Journal of Virology 2001; 75(3): 1401-1407. Maurer M, von Stebut E. Macrophage inflammatory protein-1. The International Journal of Biochemistry Cell Biology 2004; 33(10): 1882-1886. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine and Growth Factor Review 2002; 13(6): 455-481. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442(7098): 39-44. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine 1998; 4(9): 1065-1067. Nakano T, Lau GMG, Lau GML, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver International 2012; 32:339-345. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Research 2003 ; 59(1): 1-11. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science 1998; 282(5390): 938-941. Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, Schaack J, Simon FR. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochemical Journal 2004; 378(Pt 3): 919-928. Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, Selby M, Kuo G, Houghton M, Choo QL. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. Journal of Virology 1993; 67(11): 6753-6761. Rollins BJ. Chemokines. Blood 1997; 90(3): 909-928. Rottman JB, Ganley KP, Williams K, Wu L, Mackay CR, Ringler DJ. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. American Journal of Pathology 1997; 151(5): 1341-1351. Santolini E, Migliaccio G, La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. Journal of Virology 1994; 68(6): 3631-3641. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. Journal of Immunology 1999; 163(11): 6236-6243. Standiford TJ, Kunkel SL, Liebler JM, Burdick MD, Gilbert AR, Strieter RM. Gene expression of macrophage inflammatory protein-1 alpha from human blood monocytes and alveolar macrophages is inhibited by interleukin-4. American Journal of Respiratory Cell and Molecular Biology 1993; 9(2): 192-198. Street A, Macdonald A, Crowder K, Harris M. The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. The Journal of Biological Chemistry 2004; 279(13): 12232-12241. Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proceedings of the National Academy of Sciences of the United States of America 1999; 96(10): 5533-5538. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. The Journal of Biological Chemistry 2004; 279(47): 48576-48587. Tsai SC, Lin SJ, Lin CJ, Chou YC, Lin JH, Yeh TH, Chen MR, Huang LM, Lu MY, Huang YC, Chen HY, Tsai CH. Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation. Journal of Virology 2013; 87(16): 9041-9052. Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. Journal of Virology 1992; 66(3): 1476-1483. Wang J, Tian Y, Phillips KL, Chiverton N, Haddock G, Bunning RA, Cross AK, Shapiro IM, Le Maitre CL, Risbud MV. Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1. Arthritis Rheumatism 2013; 65(3): 832-842. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Molecular Cell 2005; 19(1): 111-122. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zenrecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C, Tacke F. Functional contribution of elevated circulating and hepatic non- classicial CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010; 5(6): e11049. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52297 | - |
dc.description.abstract | 感染C型肝炎病毒(hepatitis C virus, HCV)的患者有高比例的機會發展為慢性持續感染,進而造成肝纖維化、肝硬化甚至是肝細胞癌。而HCV的非結構性蛋白質5A (non-structural protein 5A, NS5A)已知會和宿主蛋白質進行交互作用,進而影響宿主細胞的訊息傳遞及基因表現,因此被認為可能是造成慢性感染的原因之一。在先前實驗室的研究中,將帶有肝臟專一性啟動子的NS5A蛋白質表現質體送入小鼠體內,挑選成功表現NS5A蛋白質的肝臟細胞,利用cDNA微陣列系統分析細胞內的基因表現,發現趨化素CCL3的基因表現量有顯著的下降。另外,在HCV複製子及穩定表現NS5A蛋白質的細胞株中也偵測到相同現象。因此,本研究進一步探討NS5A蛋白質如何調控趨化素CCL3的基因表現。 首先,相較於沒有表現NS5A蛋白質的細胞,在穩定表現NS5A蛋白質的Huh7細胞株以及轉染NS5A蛋白質表現質體的293T細胞中,均偵測到CCL3 mRNA表現量有明顯降低的情形,因此接著探討NS5A蛋白質是否會在轉錄階段調控CCL3的基因表現。透過建構一系列含有不同長度CCL3啟動子的螢火蟲冷光酶基因報導質體,分析CCL3啟動子的轉錄活性,發現在NS5A蛋白質的表現下,相較於CCL3(-996/+59),CCL3(-653/+59)、CCL3(-272/+59)以及CCL3(-173/+59)的啟動子活性均有下降的現象,其中又以CCL3(-173/+59)啟動子活性降低幅度最為顯著,因此認為NS5A蛋白質主要藉由啟動子核苷酸-173到+59區間負調控CCL3基因表現。 進一步對於此區間內的轉錄因子NF-κB及AP-1結合位分別進行定點突變,結果顯示在不表現NS5A蛋白質時,定點突變組的CCL3啟動子的活性相對於野生型組均明顯下降,因此NF-κB及AP-1對於調控CCL3啟動子的基礎活性是重要的。在NS5A蛋白質的參與下,NF-κB及AP-1結合位突變對於NS5A蛋白質負調控CCL3啟動子的能力只有些微影響,顯示NS5A蛋白質可能不是透過NF-κB及AP-1結合位,影響CCL3(-173/+59)啟動子活性。利用西方墨點法偵測NS5A蛋白質是否會影響轉錄因子在細胞內的分布及表現量,結果顯示NS5A蛋白質會促進細胞質中磷酸化的NF-κB subunit p65 (p-p65)表現,但細胞核內p-p65並未增加。另一方面,NS5A蛋白質對於p53及AP-1的表現量均無明顯影響。NS5A蛋白質是否會透過與轉錄因子結合而調控CCL3啟動子活性,以及是否會影響p-p65進入細胞核中則有待進一步證實。 | zh_TW |
dc.description.abstract | Patients who were infected with hepatitis C virus (HCV) had a high opportunity to turn to persistent infection, and might progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma. The non-structural protein 5A (NS5A) of HCV was known to interact with cellular proteins and influence signaling pathways and gene expression in host cells. Therefore, it is convinced that NS5A is one of the cause of persistent infection of HCV. In our previous studies, mice were introduced with NS5A-expressing plasmids harboring a liver-specific promoter. cDNA microarray was performed to analyze the gene expression profile in the hepatocytes which successfully expressed NS5A. The results demonstrated a decreased level of chemokine CCL3 mRNA under the expression of NS5A. The effect of NS5A was also observed in HCV replicon cells and in Huh7 cell lines stably expressing NS5A. The current study aims to further investigate how NS5A regulates the gene expression of CCL3. The down-regulation of CCL3 mRNA was first analyzed and confirmed in Huh7 cell lines stably expressing NS5A and in 293T cells transfected with NS5A-expressing plasmids. To examine whether NS5A regulates CCL3 gene expression at transcriptional level, a series of luciferase reporter plasmids carrying various lengths of CCL3 promoter were constructed and analyzed for the promoter activities. In the presence of NS5A, the promoter activities of CCL3(-653/+59), CCL3(-272/+59) and CCL3(-173/+59) were reduced as compared to the CCL3(-996/+59). Among them, the CCL3(-173/+59) showed a most significant decrease. Therefore, the negative regulation of NS5A on the CCL3 promoter activity mainly involved in the CCL3 promoter region from -173 to +59. Next, the binding site of NF-κB and AP-1 in this region was mutated individually and subjected to luciferase assay. The results demonstrated significant decreases on the luciferase activity, indicating the involvement of the NF-κB(-80/-71) and AP-1(-155/-149) binding sites on the basal promoter activity of CCL3. On the other hand, the inhibition ability of NS5A on CCL3 promoter activity was not significantly affected with the binding site being mutated. To examine whether NS5A would affect the expression and distribution of transcriptional factors, cellular proteins were fractionationed and analyzed by Western blotting. The results showed that NS5A induced the expression of phosphorylated NF-κB subunit p65 (p-p65) localized in the cytoplasm but not in nuclei. In addition, NS5A had no significant effects on the expression level of p53 and AP-1. Whether NS5A regulates CCL3 promoter activity through interacting with transcriptional factors, and whether NS5A influences the translocation of p-p65 from cytoplasm to nuclei remain to be examined. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T16:11:17Z (GMT). No. of bitstreams: 1 ntu-104-R02445132-1.pdf: 1890320 bytes, checksum: ef6045c9e8b85cb63655cda83fbb6fdb (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 摘要 2 Abstract 4 目錄 6 圖表目錄 8 壹、緒論 9 一、C型肝炎病毒的歷史 9 二、C型肝炎病毒流行病學 9 三、C型肝炎病毒治療現況 10 四、C型肝炎病毒基因體與其蛋白質 11 五、非結構性蛋白質NS5A的特性 14 六、趨化素CCL3的特性及功能 16 七、HCV對於CCL3的影響 18 八、研究目的 19 貳、材料與方法 20 一、材料 20 (一) 藥品 20 (二) 酵素 21 (三) 抗體 21 (四) 細胞培養液與轉染試劑 21 (五) 套組試劑與相關材料 22 (六) 細胞株 22 (七) 質體 23 二、方法 26 (一) DNA轉染 (DNA transfection) 26 (二) 收取細胞全蛋白質 26 (三) 蛋白質定量 26 (四) 正十二烷硫酸鈉─聚丙醯胺板膠電泳 (SDS-polyacrylamide gel electrophoresis, SDS-PAGE) 27 (五) 西方墨點法 (Western blot analysis) 28 (六) 冷光酶活性分析 (Luciferase activity assay) 29 (七) 萃取細胞RNA 30 (八) 反轉錄作用 (Reverse Transcription) 30 (九) 即時聚合酶鏈鎖反應 (Real-time polymerase chain reaction, Real-time PCR) 31 (十) 細菌轉型 (Transformation) 31 (十一) 細胞核質分離 (cell fractionation) 31 參、實驗結果 33 一、NS5A蛋白質抑制CCL3 mRNA的表現 33 二、CCL3啟動子活性分析 33 三、NS5A蛋白質對CCL3啟動子活性的影響 34 四、NS5A蛋白質與NF-κB以及AP-1結合位的關係 35 五、NS5A蛋白質對於轉錄因子表現量與分布的影響 36 肆、討論 37 伍、圖表 40 陸、參考文獻 48 附錄 57 | |
dc.language.iso | zh-TW | |
dc.title | C型肝炎病毒非結構性蛋白質NS5A對於趨化素CCL3基因之調控 | zh_TW |
dc.title | Regulation of CCL3 Gene by the Non-structural Protein 5A of Hepatitis C Virus | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王萬波(Won-Bo Wang),陳美如(Mei-Ru Chen) | |
dc.subject.keyword | C型肝炎病毒,非結構性蛋白質5A,趨化素CCL3,基因調控, | zh_TW |
dc.subject.keyword | Hepatitis C virus,NS5A,CCL3,gene regulation, | en |
dc.relation.page | 59 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.85 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。